科勁國際(06822.HK)附屬項目獲批政府出資1,500萬元
科勁國際(06822.HK)公布,全資附屬Nanoshields Technology Limited的「建立納米纖維過濾材料的智能靜電紡絲生產線」項目已經批准,可獲創新科技署的再工業化資助計劃出資1,500萬元,生產線預計將設於明年在將軍澳工業村建成的先進製造業中心。
集團已訂立協議收購四條單獨運作的納米纖維生產線,第一條已於2019年在大埔設立。目前預計其餘設備將於先進製造業中心安裝,項目總成本估計為5,000萬元,其中集團出資3,500萬元,其餘1,500萬元將由再工業化資助計劃出資。
集團認為該項目將拓展未來產品組合,使其能夠以原材料或製成品的形式進 軍高潛力市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.